Heidelberg Pharma AG published today its financial report on the first six months of 2024 (1 December 2023 – 31 May 2024).
– First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published
– Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024
– HDP-101 granted Orphan Drug Designation by the FDA
– Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
– Professor Andreas Pahl takes over as Chief Executive Officer